Primarily Resectable Pancreatic Cancer

Oncology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
neoadjuvant photon radiationN/A1 trial
Active Trials
NCT01027221Completed32Est. Sep 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Heidelberg Pharmaneoadjuvant photon radiation

Clinical Trials (1)

Total enrollment: 32 patients across 1 trials

NCT01027221Heidelberg Pharmaneoadjuvant photon radiation

Low Dose Radiation to Improve T-Cell Infiltration in Pancreatic Cancer

Start: Nov 2009Est. completion: Sep 201932 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space